2019
DOI: 10.1007/7355_2018_50
|View full text |Cite
|
Sign up to set email alerts
|

HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 15 publications
0
0
0
Order By: Relevance